why choose us

300×250 Ad Slot

Research Article: PD- Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

Date Published: 2023-07-29

Abstract:
The incidence of liver cancer has been increasing in many countries in recent decades. As the most common histological type of liver cancer, hepatocellular carcinoma (HCC) accounts for most liver cancer diagnoses and deaths. Chronic viral hepatitis and progressive liver cirrhosis are the main causes of HCC. Based on Barcelona staging (BCLC), the most suitable candidate for TACE is with intermediate-stage HCC (BCLC-B). Patients with stage BCLC-C have found survival benefits in a large number of studies, including a large longitudinal cohort study of , patients from countries and regions, documenting the experience of patients with HCC in the real world and finding that TACE is the first-line treatment for patients with HCC near stage BCLC-C. So far, the only trial that has reached the main end point for the treatment of advanced HCC between and is the TACTICS trial, which compared the efficacy of TACE plus sorafenib with TACE alone. The median mPFS of TACE plus sorafenib was . months and TACE alone was . months (HR.).

Introduction:
The incidence of liver cancer has been increasing in many countries in recent decades. As the most common histological type of liver cancer, hepatocellular carcinoma (HCC) accounts for most liver cancer diagnoses and deaths. Chronic viral hepatitis and progressive liver cirrhosis are the main causes of HCC. Based on Barcelona staging (BCLC), the most suitable candidate for TACE is with intermediate-stage HCC (BCLC-B). Patients with stage BCLC-C have found survival benefits in a large number of studies, including a…

Read more

300×250 Ad Slot